Acrivon Therapeutics (ACRV) Institutional Ownership $2.61 -2.78 (-51.58%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$2.78 +0.17 (+6.51%) As of 03/26/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Acrivon Therapeutics (NASDAQ:ACRV)CurrentInstitutional OwnershipPercentage71.62%Number ofInstitutional Buyers(last 12 months)22TotalInstitutional Inflows(last 12 months)$23.68MNumber ofInstitutional Sellers(last 12 months)11TotalInstitutional Outflows(last 12 months)$2.32M Get ACRV Insider Trade Alerts Want to know when executives and insiders are buying or selling Acrivon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ACRV Institutional Buying and Selling by Quarter Remove Ads Acrivon Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails3/12/2025 Wealthedge Investment Advisors LLC10,857$65K0.0%N/A0.035% 2/17/2025 Nuveen Asset Management LLC13,402$81K0.0%-48.0%0.043% 2/17/2025 OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 102,784$619K0.0%+29.7%0.330% 2/17/2025 Corton Capital Inc.12,159$73K0.0%N/A0.039% 2/17/2025 Bridgeway Capital Management LLC74,600$449K0.0%-3.1%0.240% 2/17/2025 Citadel Advisors LLC2,119,646$12.76M0.0%-1.0%6.807% 2/17/2025 Acorn Capital Advisors LLC405,237$2.44M1.3%N/A1.301% 2/14/2025 Northern Trust Corp117,323$706K0.0%+11.3%0.377% 2/14/2025 Dimensional Fund Advisors LP37,063$223K0.0%+20.2%0.119% 2/13/2025 Marshall Wace LLP597,794$3.60M0.0%-26.2%1.920% Get the Latest News and Ratings for ACRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/13/2025 Barclays PLC38,091$228K0.0%+14.4%0.122% 2/13/2025 Renaissance Technologies LLC49,400$297K0.0%+7.6%0.159% 2/12/2025 Trexquant Investment LP16,871$102K0.0%-44.5%0.054% 2/12/2025 JPMorgan Chase & Co.25,809$155K0.0%-24.1%0.083% 2/11/2025 American Century Companies Inc.17,588$106K0.0%+14.2%0.056% 2/6/2025 Charles Schwab Investment Management Inc.113,840$685K0.0%-2.1%0.366% 2/4/2025 Bank of New York Mellon Corp27,635$166K0.0%-6.4%0.089% 1/24/2025 China Universal Asset Management Co. Ltd.6,602$40K0.0%N/A0.021% 12/26/2024 JPMorgan Chase & Co.33,991$238K0.0%+548.3%0.109% 12/13/2024 Exome Asset Management LLC116,757$817K0.5%N/A0.375% 11/19/2024 Barclays PLC33,306$233K0.0%+51.2%0.107% 11/16/2024 Geode Capital Management LLC302,103$2.12M0.0%-2.0%0.975% 11/15/2024 Barclays PLC33,306$233K0.0%+51.2%0.108% 11/15/2024 State Street Corp225,896$1.58M0.0%+26.4%0.729% 11/12/2024 Charles Schwab Investment Management Inc.116,253$814K0.0%-19.2%0.375% 10/10/2024 Exchange Traded Concepts LLC20,348$142K0.0%-52.5%0.066% 8/16/2024 Perceptive Advisors LLC5,360,858$31.09M0.7%+78.2%17.362% 8/14/2024 Marshall Wace LLP948,866$5.50M0.0%+58.8%3.073% 8/13/2024 Sands Capital Ventures LLC2,122,605$12.31M4.1%+28.4%6.874% 8/12/2024 XTX Topco Ltd10,493$61K0.0%N/A0.034% 8/9/2024 Renaissance Technologies LLC54,500$316K0.0%-46.9%0.177% 8/9/2024 Dimensional Fund Advisors LP10,066$58K0.0%N/A0.033% 8/1/2024 Rhumbline Advisers16,209$94K0.0%+48.9%0.052% 7/26/2024 Bank of New York Mellon Corp36,632$212K0.0%+50.1%0.119% 5/15/2024 Baker BROS. Advisors LP52,885$378K0.0%N/A0.234% 5/14/2024 American International Group Inc.6,016$43K0.0%+39.2%0.027% 5/10/2024 Vanguard Group Inc.507,185$3.63M0.0%+6.6%2.241% 1/5/2024 Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060% 11/13/2023 Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020% 9/21/2023 Barclays PLC14,263$184K0.0%-16.0%0.065% Your Wealth is Under Attack (Ad)Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.Click here now to see how to stop them in their tracks!8/10/2023 AAF Wealth Management LLC10,678$138K0.1%N/A0.049% 7/20/2023 Exchange Traded Concepts LLC11,709$152K0.0%N/A0.053% 5/8/2023 Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798% 2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360% 2/14/2023 RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028% 2/13/2023 Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913% 2/10/2023 NEA Management Company LLC481,677$4.44M0.2%N/A2.306% 2/1/2023 Bank of Montreal Can42,444$545K0.0%N/A0.203% (Data available from 1/1/2016 forward)Remove Ads ACRV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACRV shares? During the previous two years, 31 institutional investors and hedge funds held shares of Acrivon Therapeutics. The most heavily invested institutionals were Perceptive Advisors LLC ($31.09M), Citadel Advisors LLC ($12.76M), Sands Capital Ventures LLC ($12.31M), Vanguard Group Inc. ($3.63M), Marshall Wace LLP ($3.60M), Acorn Capital Advisors LLC ($2.44M), and Federated Hermes Inc. ($2.16M).Learn more on ACRV's institutional investors. What percentage of Acrivon Therapeutics stock is owned by institutional investors? 71.62% of Acrivon Therapeutics stock is owned by institutional investors. Learn more on ACRV's institutional investor holdings. Which institutional investors have been buying Acrivon Therapeutics stock? Of the 24 institutional investors that purchased Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Perceptive Advisors LLC ($2.35M), Sands Capital Ventures LLC ($470K), Acorn Capital Advisors LLC ($405.24K), Marshall Wace LLP ($351.40K), Exome Asset Management LLC ($116.76K), Baker BROS. Advisors LP ($52.89K), and State Street Corp ($47.23K). How much institutional buying is happening at Acrivon Therapeutics? Institutional investors have bought a total of 4,026,349 shares in the last 24 months. This purchase volume represents approximately $23.99M in transactions. Which Acrivon Therapeutics major shareholders have been selling company stock? Of the 13 institutional investors that sold Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Federated Hermes Inc. ($287.71K), Marshall Wace LLP ($212.07K), Renaissance Technologies LLC ($48.10K), Charles Schwab Investment Management Inc. ($30.12K), Exchange Traded Concepts LLC ($22.52K), Citadel Advisors LLC ($20.98K), and Trexquant Investment LP ($13.51K). How much institutional selling is happening at Acrivon Therapeutics? Institutional investors have sold a total of 668,828 shares in the last 24 months. This volume of shares sold represents approximately $5.76M in transactions. Related Companies Maravai LifeSciences Institutional Ownership Dianthus Therapeutics Institutional Ownership LENZ Therapeutics Institutional Ownership CorMedix Institutional Ownership Organogenesis Institutional Ownership Arbutus Biopharma Institutional Ownership Sana Biotechnology Institutional Ownership ChromaDex Institutional Ownership KalVista Pharmaceuticals Institutional Ownership MeiraGTx Institutional Ownership This page (NASDAQ:ACRV) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
